MedTrace Logo

A Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma

NCT05013801 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2022-11-01

No results posted yet for this study

Summary

This is a single centre, 2-cell, single blinded full-face (products applied at lesional sites) study to evaluate changes in melasma through a cosmetic facial serum formulation and marketed 2% Hydroquinone product

Conditions

  • Melasma

Interventions

OTHER

Cosmetic facial serum Q69

Cosmetic facial serum

DRUG

2% Hydroquinone

2% Hydroquinone cream

Sponsors & Collaborators

  • Shanghai Skin Disease and Venereal Disease Hospital

    collaborator OTHER

  • Unilever R&D

    lead INDUSTRY

Principal Investigators

  • Yimei Tan, MD · Shanghai Skin Disease Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-06
Primary Completion
2022-02-25
Completion
2022-02-25

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05013801 on ClinicalTrials.gov